Kornimate/medical-research-clean huggingface dataset:
implementation of a respiratory physiotherapy program in post covid-19 patients through tele-assistance

Conditions: Covid19- Coronavirus- Sars-cov-2

Summary: the objective of this research project is to scientifically evidence a pulmonary rehabilitation program that was initiated altruistically during the confinement of those patients who had suffered from covid-19, through an online platform. patients are connected telematically 3 times a week from april 6, 2020 to perform the physical therapy program. due to the clinical improvements that have been referred by patients, they began to take objective data. our goal is to know if a telematic respiratory therapy program in post-covid 19 patient, improves the level of anxiety, dyspnea on effort, improves quality of life and oxygenation.

patients affected by covid- 19 have long periods of convalescence at home. this fact, together with the measures of social isolation, has contributed to act from a new therapeutic paradigm with the implementation of telematic rehabilitation programs. on april 6, 2020 the online platform was born under the name "respiratory physiotherapy; telematic assistance in patients with covid-19 sequelae". we want to quantify the chest physiotherapy online program. hypothesis; an online respiratory physiotherapy program offers improvements in quality of life, dyspnea and anxiety to patients who have suffered covid-19. objectives; general objective; to improve the pulmonary function of patients who have suffered from covid-19 infection through an online respiratory physiotherapy program. secondary objectives; * to improve the sensation of dyspnea; quantified by the malher and borg scale * to normalize breathing rate * to improve oxigenation; pulse-oximetry * to improve the quality of life; quantified euroqol- 5d * to improve the feeling of anxiety; quantified by the stai questionnaire methodology/study design; this is a program that was born under a very special need and circumstance, as is the coronavirus pandemic. the aim was to use respiratory tele-rehabilitation through an online platform with patients affected by coronavirus. the study is voluntary, the patient can stop the program at any time he or she considers appropriate. all of this is informed in the consent form that you give us, duly signed. i

Eligibility criteria:
inclusion criteria: * patients in the recovery phase, hospitalised or at home. * patients diagnosed with positive pcr for covid-19 * patient with sensation of dyspnea * patient able to sit still exclusion criteria: * patients admitted to intensive care and/or hemodynamically unstable * patients connected to mechanical ventilation * patients who do not have integrated cognitive abilities * patients who are receiving other respiratory rehabilitation programs * patients without adecuate technologies ( wifi, computer, email, zoom)

Keywords: chest physiotherapy covid19 pulmonary rehabilitation covid19 physical therapy coronavirus
diagnostic value of fecal calprotectin in disorders of the upper gastrointestinal tract

Conditions: Peptic Esophagitis; Peptic Ulcer; Functional Dyspepsia; Irritable Bowel Syndrome; Inflammatory Bowel Diseases

Summary: fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. however, the diagnostic value of calprotectin has never been tested in this setting. the aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.


Eligibility criteria:
inclusion criteria: * all patients referred for upper gastrointestinal endoscopy for any reason * older than 18 years exclusion criteria: * patients who are not able to provide informed consent * patients who are not able to provide a stool sample
a study of bms-824393 in combination with peginterferon alfa-2a (pegasys) and ribavirin (copegus) in treatment naive subjects with chronic hepatitis c virus genotype i

Conditions: Chronic Hepatitis C Virus Genotype 1

Summary: based on 12-week on-treatment data, at least 1 dose of bms-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegifnα/rbv for treatment of chronically infected hepatitis c virus genotype 1 treatment-naive subjects.


Eligibility criteria:
inclusion criteria: * treatment-naive subjects with genotype 1 chronic hcv * hcv rna ≥ 100,000 iu/ml at screening * seronegative for hiv and hbsag * liver biopsy within prior 2 years demonstrating no cirrhosis exclusion criteria: * any evidence of liver disease other than hepatitis c * diagnosed or suspected hepatocellular carcinoma * laboratory values: neutrophil count \< 1500 cells/μl, platelet count \< 90,000/μl; hemoglobin ≤ 12 g/dl (120g/l) for women and ≤ 13 g/dl (130 g/l) for men * cirrhosis
mhealth for breast cancer survivors with insomnia

Conditions: Breast Cancer Survivor; Insomnia

Summary: the aim of this study is to determine the impact of the voice-activated smart speaker cbt-i components on insomnia symptoms among breast cancer survivors using a randomized clinical trial.

this study is a phase ii sbir to further test efficacy of a voice-activated technology to deliver components of cognitive behavioral therapy for insomnia (cbt-i) to breast cancer survivors (bcs) compared to a web-based control. participants will be randomly assigned to the voice-activated or web-based treatment arms and will complete a 6-week intervention.

Eligibility criteria:
inclusion criteria: * willingness to maintain a consistent dosing pattern if currently taking sleep medications or using cannabis for sleep * females; age 18+ * self-reported or documented diagnosis of breast cancer stage i-iii or stage iv ecog 0-1 * completed curative treatment (surgery, radiation, chemotherapy) \> 3 months prior to enrollment \[ongoing adjuvant therapy permitted\] * has not undergone other behavioral sleep treatment within the prior 12 months * score greater than or equal to 8 on the insomnia severity index * able to understand and speak english exclusion criteria: * diagnosed, untreated obstructive sleep apnea syndrome, narcolepsy, restless leg syndrome, periodic limb movement disorder, delayed sleep phase syndrome, central apnea * bi-polar disorder, schizophrenia, initiation of psychological treatment within three months, alcohol or drug abuse in the prior year (alcohol \>2 drinks/day or consuming 5+ drinks in a single day in the prior month). (moderate adhd, depression and anxiety will not be exclusion criteria.) * shift-work in the prior three months or anticipated during the study time * planned regular travel out of time zone (\>1 hour) during the study period. * currently or planning to become pregnant during the study period

Keywords: breast cancer survivor insomnia mhealth digital health cognitive behavioral therapy for insomnia (cbt-i)
a study to investigate the effect of rifampicin on the uptake and breakdown of act-246475 in healthy subjects

Conditions: Healthy Subject

Summary: the study will investigate the effect of rifampicin on the uptake and breakdown of act-246475 in healthy subjects


Eligibility criteria:
inclusion criteria: * signed informed consent in a language understandable to the subject prior to any study-mandated procedure * healthy male and female subjects aged between 18 and 65 years (inclusive) at screening * body mass index of 18.0 to 30.0 kg/m2 (inclusive) at screening * systolic blood pressure 100-145 mmhg, diastolic blood pressure 50-90 mmhg, and pulse rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on day -1 of the first period * hematology and coagulation test results not deviating from the normal range to a clinically relevant extent at screening and on day -1 of the first period * women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on day- 1 of the first treatment period and must agree to consistently and correctly use a highly effective method of contraception exclusion criteria: * previous exposure to act-246475. * previous exposure to rifampicin within 3 months prior to screening. * known hypersensitivity to p2y12 receptor antagonists or rifampicin, or to any of the rifamycins, or any of their excipients * loss of 250 ml or more of blood within 3 months prior to screening * any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol * family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers * known platelet disorders (e.g., glanzmann thromboasthenia, von willebrand disease, platelet release defect)
a decisional intervention for older adults with acute myeloid leukemia and their caregivers

Conditions: Oncology; Myeloid Leukemia, Acute; Cancer

Summary: this is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[university of rochester-geriatric oncology assessment for acute myeloid leukemia (ur-goal)\] compared to an attention control.

this is a multicenter randomized controlled trial with four sites that assesses the efficacy of a decisional intervention \[university of rochester-geriatric oncology assessment for acute myeloid leukemia (ur-goal)\] compared to an attention control. subjects will be randomized 1:1 to either the intervention arm or the attention control arm. compared to an attention control, ur-goal will improve patient distress, observed and patient-perceived shared decision making (sdm), and patient decisional conflict.

Eligibility criteria:
patients inclusion criteria: * age ≥60 years (from date of consent, confirmed on electronic medical records) * a diagnosis of aml * diagnosis can be based on the international consensus classification or world health organization * myeloid sarcoma is allowed * cancer-directed treatment has not started (e.g., hydroxyurea, leukopheresis, or treatment to temporarily decrease white blood cells is acceptable) * the patient's oncologist has been or will be enrolled on the study * english or spanish-speaking * patients without a caregiver will still be eligible to participate in the study exclusion criteria * a diagnosis of acute promyelocytic leukemia * patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures * prior cancer-directed treatment for aml (hydroxyurea is acceptable) caregivers inclusion criteria: * selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 18 or older\] with whom you discuss or who can be helpful in health-related matters." * caregiver may be paid/professional or informal caregiver * able to provide informed consent * english or spanish-speaking * caregiver may enroll any time before the patient's next clinical visit with the oncologist, following the completion of procedures in either the ur-goal intervention or attention control arms oncologists inclusion criteria: * oncologists caring for patients with aml exclusion criteria * none

Keywords: older adults geriatric oncology caregivers
neurofeedback to improve working memory in mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment (mci) has been identified as an early phase of alzheimer's disease (ad), a neurodegenerative disorder expected to affect 13.9 million americans by 2060. ad causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality. treatment intervention at the mci stage of the disease could potentially slow down the rate at which people may convert from mci to ad. increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in ad. furthermore, previous research has shown that neurofeedback (nfb) training targeting these regions can improve memory, making it a potential treatment for ad. nfb is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor. we are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with mci. results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with mci.

this is a randomized, double-blind, clinical trial to test the efficacy of gamma-neurofeedback (g-nfb) compared to a placebo (p-nfb) in individuals with mci. 112 consented participants will be randomized to receive g-nfb (n=56) or placebo-nfb (n=56) during 30-45 minute sessions twice per week for 12 weeks (24 total sessions). memory and other cognitive domains will be measured using paper and pencil and computerized tests every 4 weeks during the study and at 4 weeks post completion of study.

Eligibility criteria:
inclusion criteria: 1. meet criteria for mild cognitive impairment (mci). 2. living independently. 3. literate in english. 4. competent to participate in the informed consent process and provide voluntary informed consent. exclusion criteria: 1. frontal temporal dementia 2. active alcohol or substance use disorder within the past year. 3. brain cancer 4. stroke within the last 2 years 5. anti-epileptic medication 6. prior head injury involving loss of consciousness 7. seizure disorder 8. use of medications likely to affect cognitive function (cf. donepezil, memantine). we will not exclude for other medications but will examine their effects and include medications as covariates as appropriate (e.g., presence v. absence; anticholinergic load). 9. the potential benefits of the study do not outweigh the potential risks of the study, as determined by the pi.

Keywords: neurofeedback
norwegian adult mental health registry

Conditions: Depression; Schizophrenia; Bipolar Disorder; Eating Disorders; Anxiety Disorders; Ptsd; Personality Disorders; Adhd

Summary: "the norwegian adult mental health registry" (namhr) is a medical quality register collecting and systematizing data on patients and their treatment in specialist mental health care for adults in norway. the main purpose is to create a documentation basis for quality assurance, evaluation, and improvement of assessment and treatment for patients who are offered treatment for mental disorders in the specialist health service. the register uses automatic data capture from various existing data sources. new patients are automatically included, but given the opportunity for reservations from the register without affecting their services and treatment.


Eligibility criteria:
inclusion criteria: * residents in norway aged 18 years or older assessed and granted right to treatment in specialized mental in- and out-patient settings exclusion criteria: * persons who have reserved themselves against participation * persons already included in more specialized register for mental disorder and/or treatment

Keywords: database epidemiology mental health register
a combined mindfulness-diving protocol on emotional eating in obese patients: a prospective randomized study

Conditions: Obesity and Overweight

Summary: the goal of this clinical trial is to learn if a combined minfulness-diving program has an impact on emotional eating in adults with obesity. the main questions it aims to answer are: does the bathysmed protocol have an impact on emotional eating after the 2 months diving protocol? researchers will compare the diving program to a control group of adult patients with obesity. participants will be asked to participate in the combined mindfulness-diving protocol for 2 months, and complete the questionnaires at baseline, 2, 5, and 8 months follow up.

this unblinded randomized controlled trial is performed in the community setting, montpellier, france. adults with a bmi \> 30kg/m2 were randomly assigned (1:1) to a bathysmed® 2-month program (intervention group) therapeutic scuba-diving protocol with mindfulness exercises plus standard care, or stand-alone standard care including dietary and psychological support (control group). the primary outcome was the mean change in the emotional eating subscale of the dutch eating behaviour questionnaire (debq-ee) at 2-months as intention to treat.

Eligibility criteria:
inclusion criteria: * patients with obesity (body mass index bmi \> 30kg/m2), * adults over the age of 18 able to provide written consent * affiliated to public medical insurance. exclusion criteria: * bmi \> 45 kg/m2, * older than 60 years, * unable to walk, * known psychiatric pathology apart from anxiety and depression, * intellectual deficit, * routinely practising meditation, * a known contra-indication to scuba-diving * known past medical history of cardiac problems.

Keywords: obesity mindfulness diving exercise
benefit of orthopedic navigation in the arthroplasty of the hip

Conditions: Osteoarthritis, Hip; Arthritis, Rheumatoid; Femur Head Necrosis

Summary: this study was initiated to investigate the impact of the computer based image free navigation on the precision of the cup implantation. the implantation of the acetabular component (cup) is known to be a critical step in hip endoprosthetics. the cup position influences significantly the function, the absence of pain and the longevity of the artificial hip joint. the image free navigation system orthopilot is used to control the positioning of the cup during surgery.


Eligibility criteria:
inclusion criteria: * indication for primary cementless total hip endoprosthesis implantation with bicontact stem and plasmacup * diagnoses: primary or secondary coxarthrosis, rheumatoid arthritis, femoral head necrosis * age ≥ 50 years * asa score \<4 * patient signed the informed consent exclusion criteria: * excessive damage to the hip joint (e.g. dysplasia) * severe deformities of the pelvis, femoral bone or knee * unfeasibility of landmark palpation (e.g. due to adiposity) * acute or chronic infection * pregnancy * patients not available for follow-up-examination at the center * patients exceeding 10 msv effective radiation dose because of previous scientific or clinical exposition during the past 10 years

Keywords: navigation orthopilot hip tep tha
clinical pharmacology of p38 map kinase inhibitor, vx-745, in mild cognitive impairment due to alzheimer's disease (ad) or mild ad

Conditions: Alzheimer's Disease

Summary: this study will assess the effects of vx-745 on markers of disease in the central nervous system of patients with mci due to ad or with mild ad. the study will also evaluate the safety and tolerability of vx-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of vx-745 during dosing.


Eligibility criteria:
inclusion criteria: * age 60 - 85 (inclusive) * willing and able to provide informed consent * clinical presentation consistent with mci due to ad or of mild ad * gradual progressive decline in memory function over \>6 months * amnestic presentation on neuropsychological testing with rapid forgetting (% reduction 1.5 standard deviations below the mean) * clinical dementia rating (cdr) sum of box (sob) score ≥0.5 * mini-mental state examination (mmse) range: 20 to 30 * brain hypometabolism by 18f-2-fluoro-2-deoxyglucose (fdg)-pet * participants may be taking medications for ad, provided that the dose of these medications has been stable for \>3 months. exclusion criteria: * evidence of neurodegenerative disease other than ad * inability for any reason to undergo mri scans (e.g. pacemaker, vascular stent or stent graft). patients who require sedation for screening procedures such as mri may receive a short-acting sedative. * psychiatric disorder that would compromise ability to comply with study requirements * history of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years * significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 map kinase inhibitor and/or assessment of drug safety and efficacy * recent (\<90 days) changes to ad medications prescribed for cognitive reasons or with the potential to impact cognition * psychotropic drugs taken within 1 month. anticoagulant drugs taken within 1 week. * participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study * male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements * female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy * positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial * donation of \>500 ml of blood or blood products within 2 months * history of alcohol and/or illicit drug abuse within 6 months. * infection with hepatitis a, b or c or hiv. * any factor deemed by the investigator to be likely to interfere with study conduction